Mark A. Socinski, MD, executive medical director at AdventHealth Cancer Institute, recommends immediate comprehensive molecular testing at the time of lung cancer diagnosis. Stating that oncogenic driver mutation…
Erin M. Bertino, MD, medical oncologist at Ohio State University Comprehensive Cancer Center – James, provides a comparison of newly approved drug dacomitinib versus the other available FDA-approved…
Jessica Bauman, MD, assistant professor of hematology/oncology at Fox Chase Cancer Center, discusses recent advancements in non-small cell lung cancer (NSCLC) treatment using targeted RET-fusion mutation therapies. RET-fusion…
Julia Rotow, MD, medical oncologist at Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, reviews new treatment options for non-small cell lung cancer (NSCLC) patients. Dr. Rotow…
Rogerio C. Lilenbaum, MD, director of the Banner MD Anderson Cancer Center, discusses the ways physicians practicing in different care institutions order molecular panels for patients with nonsquamous…
Nathan A. Pennell, MD, PhD, director of the Lung Cancer Medical Oncology Program at Taussig Cancer Institute at the Cleveland Clinic, emphasizes the importance of molecular testing before…
In this video interview, Jonathan W. Goldman, MD, a health sciences clinical instructor in the Department of Medicine at the Jonsson Comprehensive Cancer Center Signal Transduction and Therapeutics…
In this video, Hatim Husain, MD, medical oncologist and associate professor of medicine for Moores Cancer Center at UCSD, explores how liquid biopsies are being incorporated into studies…
There has been an explosion of new data from targeted therapy studies since the 2017 publication of ASCO’s full clinical practice guidelines regarding systemic therapy for patients with…
Terence T. Sio, MD, MS, associate professor of radiation oncology at the Mayo Clinic and specialist in both X-ray-based and proton radiotherapies, discusses study results comparing the efficacy…